NCT02048358: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients |
|
|
| Terminated | 1 | 47 | Europe | 2B3-201, 2B3-201: glutathione PEGylated-liposomal methylprednisolone, Placebo, 5% Dextrose, Methylprednisolone hemisuccinate, Solu-Medrol | BBB-Therapeutics B.V. | Healthy Volunteers, Multiple Sclerosis | 01/15 | 02/15 | | |
